Penumbra (NYSE:PEN – Free Report) had its price target trimmed by Morgan Stanley from $235.00 to $210.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.
Other equities research analysts also recently issued reports about the company. Truist Financial reduced their price objective on Penumbra from $290.00 to $280.00 and set a buy rating for the company in a research note on Friday, March 22nd. Citigroup decreased their price target on shares of Penumbra from $300.00 to $265.00 and set a buy rating for the company in a report on Wednesday, July 10th. Needham & Company LLC reiterated a hold rating on shares of Penumbra in a research note on Wednesday, May 8th. Canaccord Genuity Group decreased their target price on shares of Penumbra from $284.00 to $272.00 and set a buy rating for the company in a research note on Wednesday, May 8th. Finally, Piper Sandler dropped their price target on shares of Penumbra from $290.00 to $260.00 and set an overweight rating on the stock in a research note on Wednesday, May 8th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Penumbra presently has an average rating of Moderate Buy and a consensus price target of $260.56.
Get Our Latest Stock Analysis on PEN
Penumbra Stock Performance
Penumbra (NYSE:PEN – Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.01). The firm had revenue of $278.70 million for the quarter, compared to analysts’ expectations of $274.94 million. Penumbra had a return on equity of 7.83% and a net margin of 8.52%. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.23 earnings per share. As a group, equities research analysts predict that Penumbra will post 2.88 EPS for the current year.
Insider Activity at Penumbra
In other Penumbra news, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $200.98, for a total transaction of $3,014,700.00. Following the transaction, the chief executive officer now owns 942,582 shares in the company, valued at $189,440,130.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $200.98, for a total value of $3,014,700.00. Following the sale, the chief executive officer now directly owns 942,582 shares of the company’s stock, valued at $189,440,130.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $188.90, for a total value of $113,340.00. Following the completion of the sale, the executive vice president now directly owns 62,888 shares in the company, valued at approximately $11,879,543.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,970 shares of company stock valued at $3,390,604. Corporate insiders own 5.00% of the company’s stock.
Institutional Trading of Penumbra
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Portside Wealth Group LLC acquired a new stake in Penumbra during the second quarter worth about $396,000. 17 Capital Partners LLC grew its holdings in shares of Penumbra by 11.7% during the 2nd quarter. 17 Capital Partners LLC now owns 1,431 shares of the company’s stock worth $258,000 after purchasing an additional 150 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Penumbra by 215.0% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,408 shares of the company’s stock valued at $613,000 after purchasing an additional 2,326 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Penumbra during the second quarter valued at approximately $233,000. Finally, Diversified Trust Co raised its stake in shares of Penumbra by 20.8% in the second quarter. Diversified Trust Co now owns 8,119 shares of the company’s stock valued at $1,461,000 after purchasing an additional 1,399 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.
Penumbra Company Profile
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Articles
- Five stocks we like better than Penumbra
- Financial Services Stocks Investing
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Parabolic Rise of This Stock Shows No Signs of Slowing
- 3 REITs to Buy and Hold for the Long Term
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.